Worth the effort? Weighing up the benefit and burden of continuous positive airway pressure therapy for the treatment of obstructive sleep apnoea in chronic tetraplegia.
Ambulatory Care
Chronic Disease
Continuous Positive Airway Pressure
/ adverse effects
Female
Humans
Interviews as Topic
Male
Middle Aged
Patient Compliance
Patient Satisfaction
Quadriplegia
/ complications
Qualitative Research
Sleep Apnea, Obstructive
/ complications
Spinal Cord Injuries
/ complications
Time Factors
Treatment Outcome
Journal
Spinal cord
ISSN: 1476-5624
Titre abrégé: Spinal Cord
Pays: England
ID NLM: 9609749
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
07
08
2018
accepted:
04
10
2018
revised:
22
09
2018
pubmed:
26
10
2018
medline:
16
4
2019
entrez:
26
10
2018
Statut:
ppublish
Résumé
Mixed methods OBJECTIVES: Continuous positive airway pressure (CPAP) therapy is the recommended treatment for obstructive sleep apnoea (OSA). The aim of this study was to estimate CPAP adherence in people with tetraplegia and OSA, and to explore the barriers and facilitators to CPAP use. Hospital outpatient department in Melbourne, Australia METHODS: People with chronic tetraplegia and OSA were commenced with auto-titrating CPAP and supported for 1 month. Semi-structured interviews were conducted with participants at one month and analysed thematically. CPAP usage was measured at 1, 6 and 12 months, with "adherent" defined as achieving more than 4 h average per night. Sixteen participants completed the study (80% male; mean age 56 (SD = 15)). Mean nightly CPAP use at one month was 3.1 h (SD = 2.5; 38% adherent), and at 6 months and 12 months were 2.6 h (SD = 2.8; 25% adherent) and 2.1 h (SD = 3.2; 25% adherent). The perceived benefit/burden balance strongly influenced ongoing use. Burden attributed to CPAP use was common, and included mask discomfort, and physical and emotional problems. Adherent participants were motivated by the immediate daytime benefits to mood, alertness and sleepiness. There was a tendency to not recognise symptoms of OSA until after they were treated. CPAP use is challenging for people with tetraplegia, who experience substantial burden from using the device. When tolerated, the proximate benefits are substantial. People with tetraplegia need more intensive support for longer to help them overcome the burdens of CPAP and benefit from the treatment.
Identifiants
pubmed: 30356181
doi: 10.1038/s41393-018-0210-z
pii: 10.1038/s41393-018-0210-z
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-254Subventions
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : 1114181
Références
Qual Health Res. 2010 Jul;20(7):873-92
pubmed: 20354236
J Rehabil Med. 2013 Nov;45(10):1016-22
pubmed: 24096367
Indian J Med Res. 2010 Feb;131:245-58
pubmed: 20308750
Curr Sleep Med Rep. 2017 Dec;3(4):272-278
pubmed: 29177130
Qual Life Res. 2017 Feb;26(2):489-503
pubmed: 27566732
Sleep. 2013 Dec 01;36(12):1929-37
pubmed: 24293768
J Spinal Cord Med. 2005;28(5):434-70
pubmed: 16869091
Arch Phys Med Rehabil. 2000 Oct;81(10):1334-9
pubmed: 11030498
Ann Intern Med. 2013 Oct 1;159(7):471-83
pubmed: 24061345
Sleep. 2017 Feb 01;40(2):
pubmed: 28364492
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001106
pubmed: 16437429
Lancet Respir Med. 2014 Oct;2(10):804-12
pubmed: 25172769
Stroke. 2011 Apr;42(4):1062-7
pubmed: 21372306
Thorax. 2018 Sep;73(9):864-871
pubmed: 29735608
Spinal Cord. 2015 Feb;53(2):145-9
pubmed: 25510191
Sleep. 1997 Apr;20(4):278-83
pubmed: 9231953
PLoS One. 2017 Jun 23;12(6):e0179916
pubmed: 28644877
Behav Sleep Med. 2016;14(1):67-84
pubmed: 25203283
Sleep Med Rev. 2014 Aug;18(4):357-66
pubmed: 24581718
OTJR (Thorofare N J). 2017 Apr;37(2):89-97
pubmed: 28196449
Sleep Med. 2010 Feb;11(2):126-30
pubmed: 20004615
Arch Phys Med Rehabil. 2007 Mar;88(3):333-7
pubmed: 17321826
Arch Phys Med Rehabil. 2012 Jul;93(7):1246-52
pubmed: 22516876
Spinal Cord. 2018 Aug;56(8):777-789
pubmed: 29515212
Sleep Med Rev. 2013 Dec;17(6):399-409
pubmed: 23618534